Scientific advisory board

About Aimm Therapeutics

Scientific advisory board

AIMM’s Scientific Advisory Board includes prestigious leadership from the fields of cancer research, immunology and infectious disease.

Bob Löwenberg, MD, PhD
Erasmus University Rotterdam, the Netherlands
Renowned for his pivotal contributions to the diagnosis and treatment of acute myeloid leukemia, Bob Löwenberg has been chairman of the Department of Hematology at the Erasmus University Medical Center and currently serves as the editor-in-chief of Blood, the journal of the American Society of Hematology.

John Mendelsohn, MD, PhD
11 January 2019: Today we got the sad message that John Mendelsohn passed away on 7 January 2019. John was an internationally acclaimed leader in medicine and a pioneer in cancer immunotherapy. AIMM was very fortunate to have a giant like John serving as a member of AIMM’s Scientific advisory board since 2013. AIMM is indebted to John for his contributions to developing AIMM’s pipeline of innovative anti cancer antibodies.

Hidde Ploegh, PhD
Whitehead Institute, MIT, Cambridge, USA
World-leading immunologist, Hidde Ploegh is a faculty member at the Whitehead Institute for Biomedical Research and professor of biology at the Massachusetts Institute of Technology. The Ploegh Lab studies the various tactics that viruses employ to evade human immune responses and how the immune system distinguishes pathogens from healthy cells.

Menno de Jong, MD, PhD, FRCP Edin
Amsterdam Medical Center, University of Amsterdam, the Netherlands
Specializing in infectious disease research and emerging avian and human influenza infections, Menno de Jong heads the Department of Medical Microbiology at the Academic Medical Center, University of Amsterdam, is a professor of Clinical Virology and heads the Laboratory of Virology at the Oxford University Clinical Research Unit (OUCRU). In 1991, de Jong established the OUCRU at the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam.

Ton Schumacher, PhD
The Netherlands Cancer Institute
Using an engineering approach towards immunology, the Schumacher lab has provided seminal insights into how the T cell-based immune system recognizes human cancer cells, and how cancer-specific immune responses can be created. Schumacher is currently deputy director of The Netherlands Cancer Institute, professor of Immunotechnology at Leiden University, and Cancer Immunotherapy Dream Team member. The international initiative, Stand Up Cancer, has assembled interdisciplinary Dream Teams to advance translational research in the treatment of cancer.